Waiting for reimbursement of new medicines in canada: It's time for a rethink

PharmacoEconomics

Volumn 26, Issue 8, 2008, Pages 629-632

  Skinner, Brett J ^a  

^a Fraser Institute   (Canada)

Author keywords

Drug utilisation; Formularies; Health insurance; Health policy; Pricing; Reimbursement

Indexed keywords

CANADA; HEALTH CARE ACCESS; NOTE; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; REIMBURSEMENT;

CANADA; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; NATIONAL HEALTH PROGRAMS; PHARMACEUTICAL PREPARATIONS; PRIVATE SECTOR; REIMBURSEMENT MECHANISMS; TIME FACTORS;

EID: 47249152818     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826080-00001     Document Type: Note

References (10)

1. DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 2001: 69 (5): 297-307
2. Adams CP, Brantner VV. New drug development: estimating entry from human clinical trials [US Federal Trade Commission working paper 262]. Washington, DC: US FTC, 2003
3. Adams CP, Brantner VV. Estimating the cost of new drug development: is it really $802 million? Health Aff 2006; 25 (2): 420-28
4. DiMasi JA, Hansen RW, Grabowski HG, et al. Research and development costs for new drugs by therapeutic category: a study of the US pharmaceutical industry. Pharmacoeconomics 1995; 7 (2): 152-69
5. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 1993; 22 (2): 151-85
6. Skinner BJ, Rovere M. Access delayed, access denied 2008: waiting for new medicines in Canada. Vancouver (BC): Fraser Institute, 2008 [online]. Available from URL: http://www. fraserinstitute.org/commerce.web/product_files/ AccessDelay edAccessDenied2008.pdf [Accessed 2008 Jun 18]
7. iMAM® [propietary database]. Brogan Inc., 2007 [online]. Available from URL: http://www.broganinc.com/english/products/index.html [Accessed 2008 Jun 18]
8. Health Canada. 2006 Annual drug submission performance report: part I. Therapeutic products directorate. Ottawa (ON): Health Canada, Health Products and Food Branch, 2007 [on-line]. Available from URL: http://www.hc-sc.gc.ca/dhp- mps/prodpharma/applic-demande/docs/perform-rendement/ar-ra/ tpd_dpt_annual_annuel_07-eng.php [Accessed 2008 Jun 18]
9. Health Canada. 2006 Annual drug submission performance report: part II. Biologics and genetic therapies directorate. Ottawa (ON): Health Canada, Health Products and Food Branch, 2007 [online]. Available from URL: http://www.hcsc.gc.ca/dhp-mps/prodpharma/applic-demande/docs/performrendement/ ar-ra/bgtd_dpbtg_annual_annuel_07-eng.php [Accessed 2008 Jun 18]
10. Newhouse JP, Keeler EB, Willard Jr GM, et al. Free for all? Lessons from the RAND health insurance experiment: a RAND study. Cambridge (MA): Harvard University Press, 1993